Astria Therapeutics (ATXS) Competitors $3.92 -0.37 (-8.53%) Closing price 03:59 PM EasternExtended Trading$3.92 +0.00 (+0.03%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. COLL, NTLA, RCUS, AVDL, SYRE, PHVS, CRMD, NAGE, CVAC, and BCAXShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Arcus Biosciences (RCUS), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Pharvaris (PHVS), CorMedix (CRMD), Niagen Bioscience (NAGE), CureVac (CVAC), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Collegium Pharmaceutical Intellia Therapeutics Arcus Biosciences Avadel Pharmaceuticals Spyre Therapeutics Pharvaris CorMedix Niagen Bioscience CureVac Bicara Therapeutics Astria Therapeutics (NASDAQ:ATXS) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability. Which has more volatility and risk, ATXS or COLL? Astria Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Do insiders & institutionals believe in ATXS or COLL? 99.0% of Astria Therapeutics shares are owned by institutional investors. 2.9% of Astria Therapeutics shares are owned by insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor ATXS or COLL? In the previous week, Astria Therapeutics had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 15 mentions for Astria Therapeutics and 12 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.36 beat Astria Therapeutics' score of -0.28 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astria Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ATXS or COLL more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Astria Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -43.58% -29.36% Collegium Pharmaceutical 14.78%104.67%18.38% Which has preferable valuation and earnings, ATXS or COLL? Collegium Pharmaceutical has higher revenue and earnings than Astria Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$72.89M-$1.87-2.14Collegium Pharmaceutical$664.28M1.43$48.15M$1.2224.17 Does the MarketBeat Community favor ATXS or COLL? Astria Therapeutics received 184 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. Likewise, 73.25% of users gave Astria Therapeutics an outperform vote while only 65.38% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformAstria TherapeuticsOutperform Votes57573.25% Underperform Votes21026.75% Collegium PharmaceuticalOutperform Votes39165.38% Underperform Votes20734.62% Do analysts rate ATXS or COLL? Astria Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 649.25%. Collegium Pharmaceutical has a consensus price target of $43.80, suggesting a potential upside of 48.54%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Astria Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryAstria Therapeutics and Collegium Pharmaceutical tied by winning 9 of the 18 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$226.30M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-1.928.9726.6219.77Price / SalesN/A253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book1.206.486.814.53Net Income-$72.89M$143.98M$3.23B$248.18M7 Day Performance0.86%3.37%4.05%1.06%1 Month Performance-2.58%7.83%11.64%14.68%1 Year Performance-56.48%-2.24%17.11%6.87% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics2.0233 of 5 stars$3.92-8.5%$30.00+664.5%-55.3%$221.45MN/A-1.8830News CoverageGap DownCOLLCollegium Pharmaceutical4.113 of 5 stars$29.83-1.3%$43.80+46.8%-12.3%$958.50M$664.28M12.86210News CoveragePositive NewsNTLAIntellia Therapeutics4.6481 of 5 stars$9.06+6.6%$36.90+307.3%-62.6%$938.46M$45.57M-1.67600Analyst ForecastHigh Trading VolumeRCUSArcus Biosciences3.5699 of 5 stars$8.70+1.6%$25.67+195.0%-47.4%$921.20M$141M-2.76500Positive NewsGap DownAVDLAvadel Pharmaceuticals2.2178 of 5 stars$9.35+3.8%$19.43+107.8%-40.3%$903.48M$194.45M-11.8470Positive NewsSYRESpyre Therapeutics2.3533 of 5 stars$14.88-2.0%$53.40+258.9%-58.2%$896.91M$890,000.00-1.99100Positive NewsPHVSPharvaris1.2946 of 5 stars$16.69+0.8%$40.67+143.7%-16.5%$865.92MN/A-5.9630CRMDCorMedix2.138 of 5 stars$12.75+3.8%$15.00+17.6%+153.9%$864.77M$82.55M-15.7430Positive NewsNAGENiagen BioscienceN/A$10.93-0.2%N/AN/A$860.96M$107.93M64.29120CVACCureVac3.7447 of 5 stars$3.87+4.0%$14.00+261.8%+25.9%$834.54M$535.18M7.04880News CoverageUpcoming EarningsGap DownBCAXBicara Therapeutics1.649 of 5 stars$15.21+5.1%$32.00+110.4%N/A$829.49MN/A0.0032Analyst RevisionGap Down Related Companies and Tools Related Companies Collegium Pharmaceutical Competitors Intellia Therapeutics Competitors Arcus Biosciences Competitors Avadel Pharmaceuticals Competitors Spyre Therapeutics Competitors Pharvaris Competitors CorMedix Competitors Niagen Bioscience Competitors CureVac Competitors Bicara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
